JP7130879B2 - ベンゾアゼピン化合物含有医薬組成物 - Google Patents

ベンゾアゼピン化合物含有医薬組成物 Download PDF

Info

Publication number
JP7130879B2
JP7130879B2 JP2021540578A JP2021540578A JP7130879B2 JP 7130879 B2 JP7130879 B2 JP 7130879B2 JP 2021540578 A JP2021540578 A JP 2021540578A JP 2021540578 A JP2021540578 A JP 2021540578A JP 7130879 B2 JP7130879 B2 JP 7130879B2
Authority
JP
Japan
Prior art keywords
metal salt
pharmaceutical composition
formula
minutes
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519343A (ja
Inventor
遠見彦 千原
真悟 宇野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2022519343A publication Critical patent/JP2022519343A/ja
Priority to JP2022129393A priority Critical patent/JP2022163190A/ja
Application granted granted Critical
Publication of JP7130879B2 publication Critical patent/JP7130879B2/ja
Priority to JP2025024093A priority patent/JP2025081484A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021540578A 2019-03-28 2020-03-27 ベンゾアゼピン化合物含有医薬組成物 Active JP7130879B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129393A JP2022163190A (ja) 2019-03-28 2022-08-15 ベンゾアゼピン化合物含有医薬組成物
JP2025024093A JP2025081484A (ja) 2019-03-28 2025-02-18 ベンゾアゼピン化合物含有医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019064357 2019-03-28
JP2019064357 2019-03-28
PCT/JP2020/013935 WO2020196816A1 (en) 2019-03-28 2020-03-27 Benzoazepine compound-containing pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129393A Division JP2022163190A (ja) 2019-03-28 2022-08-15 ベンゾアゼピン化合物含有医薬組成物

Publications (2)

Publication Number Publication Date
JP2022519343A JP2022519343A (ja) 2022-03-23
JP7130879B2 true JP7130879B2 (ja) 2022-09-05

Family

ID=70289832

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021540578A Active JP7130879B2 (ja) 2019-03-28 2020-03-27 ベンゾアゼピン化合物含有医薬組成物
JP2022129393A Pending JP2022163190A (ja) 2019-03-28 2022-08-15 ベンゾアゼピン化合物含有医薬組成物
JP2025024093A Pending JP2025081484A (ja) 2019-03-28 2025-02-18 ベンゾアゼピン化合物含有医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022129393A Pending JP2022163190A (ja) 2019-03-28 2022-08-15 ベンゾアゼピン化合物含有医薬組成物
JP2025024093A Pending JP2025081484A (ja) 2019-03-28 2025-02-18 ベンゾアゼピン化合物含有医薬組成物

Country Status (7)

Country Link
US (1) US20220152064A1 (enExample)
EP (1) EP3946362A1 (enExample)
JP (3) JP7130879B2 (enExample)
KR (1) KR20210144811A (enExample)
CN (1) CN113631169A (enExample)
EA (1) EA202192635A1 (enExample)
WO (1) WO2020196816A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521397A (ja) 2005-12-27 2009-06-04 大塚製薬株式会社 水溶性ベンゾアゼピン化合物及び医薬組成物
JP2015134837A (ja) 2007-06-26 2015-07-27 大塚製薬株式会社 医薬
JP2016533317A (ja) 2013-10-15 2016-10-27 大塚製薬株式会社 多発性嚢胞腎の予防及び／又は治療薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192646A1 (ru) * 2019-03-28 2021-12-09 Оцука Фармасьютикал Ко., Лтд. Лиофилизированная композиция, содержащая соединение бензоазепина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521397A (ja) 2005-12-27 2009-06-04 大塚製薬株式会社 水溶性ベンゾアゼピン化合物及び医薬組成物
JP2015134837A (ja) 2007-06-26 2015-07-27 大塚製薬株式会社 医薬
JP2016533317A (ja) 2013-10-15 2016-10-27 大塚製薬株式会社 多発性嚢胞腎の予防及び／又は治療薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sato N et al.，P278 Pharmacokinetics, pharmacodynamics and efficacy of OPC-61815, prodrug of tolvaptan for intravenous administration, in patients with congestive hearty failure，Poster Presentation--31-Pharmacology and Pharmacotherapy，2020年01月13日
埼玉協同病院薬剤科，ＤＩニュース，2017年03月25日，No.572，pp.1-4，kyoudou-hp.com/DInews/2017/572.pdf

Also Published As

Publication number Publication date
US20220152064A1 (en) 2022-05-19
JP2022519343A (ja) 2022-03-23
EA202192635A1 (ru) 2021-12-10
JP2022163190A (ja) 2022-10-25
EP3946362A1 (en) 2022-02-09
KR20210144811A (ko) 2021-11-30
CN113631169A (zh) 2021-11-09
WO2020196816A1 (en) 2020-10-01
JP2025081484A (ja) 2025-05-27

Similar Documents

Publication Publication Date Title
US5589491A (en) Injection and injection kit containing omeprazole and its analogs
US6548079B1 (en) Moxifloxacin formulation containing common salt
KR102034606B1 (ko) 데옥시콜린산 및 그의 염들의 제형물들
JP7043156B2 (ja) ベンゾアゼピン化合物含有凍結乾燥組成物
EP3305298B1 (en) Formulations of deoxycholic acid and salts thereof
JP2006008684A (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
JP7130879B2 (ja) ベンゾアゼピン化合物含有医薬組成物
HK40063746A (en) Benzoazepine compound-containing pharmaceutical composition
HK40063745B (zh) 含有苯并氮杂卓化合物的冻干组合物
HK40063745A (en) Benzoazepine compound-containing freeze-dried composition
MXPA00000973A (es) Composiciones inyectables de alatrofloxacina previamente mezcladas.
EA045403B1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина
JP2002080361A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
JPH08217675A (ja) インフルエンザ治療剤
HK40011534A (en) Formulations of deoxycholic acid and salts thereof
JPS6330422A (ja) 抗悪性腫瘍効果増強剤
HK1182629B (en) Formulations of deoxycholic acid and salts thereof
HK1182629A (en) Formulations of deoxycholic acid and salts thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210730

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220824

R150 Certificate of patent or registration of utility model

Ref document number: 7130879

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250